EULAR Updates Recommendations for Managing RA
BARCELONA, Spain — Patients with rheumatoid arthritis (RA) who have not responded to first-line methotrexate therapy should be started on a biologic or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD), according to new recommendations by the European Alliance of Associations for Rheumatology (EULAR).
These updated recommendations contain five overarching principles and nine recommendations — two fewer than those in the 2022 iteration. Several of the recommendations remain unchanged, and a few were merged or modified to provide greater clarity.
'The availability of an increasing number of good drugs and increasing evidence due to wonderful clinical trials made the task force in charge of these recommendations produce increasingly leaner recommendations,' said Josef S. Smolen, MD, of the Medical University of Vienna, Vienna, Austria, who presented them at the EULAR 2025 Annual Meeting. 'It's nice because it makes life simpler.'
Josef S. Smolen, MD
EULAR continues to recommend methotrexate and short-term glucocorticoids as the first treatment strategy for RA. (In the case of contraindications, leflunomide or sulfasalazine should be considered.)
'We have yet to find something that beats methotrexate plus glucocorticoids [as a first therapy strategy],' Smolen said.
However, if the treatment target is not reached with this first conventional synthetic (cs)DMARD approach, then the patient should be started on a b/tsDMARD.
Second-Line Therapy With b/tsDMARDs
This update eliminates treatment based on stratification according to poor prognostic factors, such as the presence of autoantibodies or high disease activity. In the 2022 recommendations, patients without these factors could start another csDMARD, whereas those with these poor prognostic factors could start a b/tsDMARD.
'The task force felt that the stratification was not necessary because if you fail methotrexate plus glucocorticoids, you already have a bad prognostic sign,' Smolen explained.
Alexandre Sepriano, MD, PhD, an assistant professor of rheumatology at NOVA University Lisbon, Lisbon, Portugal, thought this change was the 'most important modification' to these RA treatment guidelines and would have 'significant implications for clinical practice.' He co-moderated the session where these updated recommendations were presented.
Alexandre Sepriano, MD, PhD
'In some countries (eg, the United Kingdom), patients previously had to fail two csDMARDs before being eligible for a biologic or JAK inhibitor,' added Kim Lauper, MD, PhD, of Geneva University Hospitals, Geneva, Switzerland, the other moderator of the session. 'This new recommendation could help support policy changes that allow for earlier escalation, potentially helping more patients reach remission faster.'
EULAR still recommends that b/tsDMARDs be combined with a csDMARD. In patients who cannot use a csDMARD as a co-medication, interleukin 6 inhibitors and JAK inhibitors 'may have some advantages compared with other bDMARDs,' the recommendations state.
More Research Needed on JAK Inhibitors
EULAR advises that clinicians should evaluate cardiovascular and malignancy risk factors before prescribing a JAK inhibitor. While the ORAL Surveillance trial found that the risk for major cardiovascular events and cancer was more common with tofacitinib than with TNF inhibitors, patient registries have not shown these same patterns, Smolen said. More randomized controlled trials are therefore needed to understand what could be driving the risk, he added.
Kim Lauper, MD, PhD
'We're awaiting more data, and we would love to see and understand the mechanisms that led to a higher incidence of malignancies and cardiovascular events [in the ORAL Surveillance trial],' he said.
Once a patient achieves sustained remission, they can taper to a lower DMARD dose; however, the new guidelines emphasize the importance of remaining on DMARDs and not stopping them entirely, Smolen said.
'Now, we more clearly state that this task force, based on newer data, felt that continuation of DMARDs — whether traditional [synthetic], biologic, or targeted synthetic DMARDs — is recommended, but dose reduction may be considered,' he continued.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Yili Secures Four World Dairy Innovation Awards at the 18th Global Dairy Congress
AMSTERDAM, June 23, 2025 /PRNewswire/ -- On June 18–19, the Global Dairy Congress 2025 was held in Amsterdam. At the forum, Dr. Ignatius Szeto, Assistant President of Yili Group, delivered a keynote speech titled "Innovating for a sustainable future" and shared Yili's latest innovative practices. On the opening day, the organizers unveiled the winners of the 2025 World Dairy Innovation Awards. Yili secured four World Dairy Innovation Awards and six commended Awards. Notably, Yili has claimed the World Dairy Innovation Awards for six consecutive years. Dr. Carolien van Loo, Head of Yili Innovation Center Europe, attended a roundtable forum on maternal and infant nutrition and breast milk research. Multiple star products from Yili's top infant formula brand, Pro-Kido, were featured as the Congress's officially designated products. At the Industry Leadership Forum, Dr. Ignatius Szeto systematically introduced Yili's global innovation practices across product innovation, maternal and infant nutrition, advanced dairy processing, and sustainable development. He emphasized: "Innovation is the driving force behind the sustainable prosperity of the dairy industry. Remaining consumer-centric, Yili dedicates itself to nutrition and health research across the full life cycle, keeps making core technological breakthroughs, and accelerates the commercialization of fundamental research outcomes—all of which contribute to the advancement of the global dairy sector." During the roundtable forum themed "Innovation in Pioneering a New Future for Global Maternal and Infant Health", Dr. Ignatius Szeto and Dr. Carolien van Loo engaged in in-depth discussions with experts including Jean-Christophe Kremer, Secretary-General of the International Special Dietary Foods Industries, and Richard Hall, Chair of FoodBev Media. The discussions focused on research about breast milk and maternal and infant nutrition. Dr. Carolien van Loo highlighted that Yili Innovation Center Europe, in collaboration with institutions such as Wageningen University and Donders Institute for Brain, Cognition and Behaviour, has conducted pioneering research on HMOs. Their breakthrough findings demonstrated HMOs' health benefits in enhancing immunity, protecting gut barrier function, preventing pathogen adhesion, and promoting cognitive development. The annual World Dairy Innovation Awards were announced at the event. This year, Yili Group secured four awards for its high-quality products and outstanding performance in innovation. Zhenlao Light Cream from Yijiahao Cheese won the Best Artisan Product, Joyday Crunchy Choco Lava was awarded Best Ice Cream, Yili's patented multi-enzymatic lactose-to-GOS technology: Boosting Gut Health in Qinghuo Adult Milk Powder claimed the Best Intolerance-Friendly Innovation, and Satine Carbon-Reduced Organic Milk won the Best CSR/Sustainability Initiative. Staying true to its philosophy of "No Innovation, No Future," Yili consistently increases its R&D investment to provide comprehensive nutrition solutions for consumers across the full life cycle. To date, Yili has established 15 innovation centers across Asia, Europe, and Oceania. Moving forward, Yili will continue to align its strategy with consumer needs, drive growth through technological innovation, and foster global partnerships to deliver enhanced health value for consumers worldwide, aiming to enable the sustainable prosperity of the dairy industry. View original content to download multimedia: SOURCE Yili Group Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Medscape
an hour ago
- Medscape
CMR in MINOCA Linked to Improved Diagnosis and Management
TOPLINE: In a prospective study of over 300 patients with myocardial infarction with nonobstructive coronary arteries (MINOCA), cardiovascular magnetic resonance (CMR) was associated with meaningful changes in clinical diagnosis and/or management in 63% of patients and a similar increase in diagnostic certainty. METHODOLOGY: Previous CMR studies in MINOCA have focused on radiologic yield — a limited metric that does not reflect real‐world clinical utility. Prospective data on patient care are lacking. This prospective study conducted in Australia and the UK assessed the impact of CMR on diagnosis and management in 320 patients with MINOCA (mean age, 55.6 years; 52% men) recruited between January 2019 and July 2023. Patients were included if they had a hospital admission with acute features consistent with the Fourth Universal Definition of Myocardial Infarction, no obstructive coronary artery disease on angiography, and a clinician assessment indicating acute myocardial infarction as the most likely presentation. The treating cardiologists completed a questionnaire before and after CMR to record their working diagnosis, rate diagnostic certainty on a 1-10 scale (10 = most certain), and specify intended management, including medications and follow-up testing. The primary endpoint was a composite of change in clinical diagnosis or management after CMR. TAKEAWAY: CMR was associated with a change in diagnosis or management in 63% of patients (P < .001), with diagnosis revised in 38% and management changed in 50%. Diagnostic certainty increased significantly from a median score of 6-8 after CMR (P < .001), and diagnostic confidence numerically increased in 63% of patients. The absence of coronary atheroma, a pre-CMR diagnostic certainty score ≤ 5, and early CMR (performed within 14 days of hospital presentation) independently predicted a change in diagnosis or management, with 80% of patients with all three predictors vs 40% of those with none meeting the primary outcome. Of 172 patients initially prescribed dual antiplatelet therapy, 66 (38%) had it deprescribed following CMR, yielding a number needed to test of 3. IN PRACTICE: 'Integration of CMR into diagnostic imaging pathways may be reasonable to augment clinical diagnosis and management; however, further cost-effectiveness analyses are now warranted,' the study authors wrote. SOURCE: This study was led by Adil Rajwani, PhD, of the Royal Perth Hospital, Perth, Australia. It was published online on June 13, 2025, in Heart. LIMITATIONS: The study was limited by the impracticality of conducting a bias-free randomized trial of CMR vs no CMR. It was also limited by the assessment of CMR's impact only immediately after imaging, potentially missing later clinical insights. Medication protocols were not standardized, and the limited use of additional diagnostics such as optical coherence tomography may have influenced the findings. DISCLOSURES: This study was funded by a grant from the Royal Perth Hospital Medical Research Foundation in Australia. The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Associated Press
2 hours ago
- Associated Press
Bloomberg's War on Harm Reduction Faces Consumer Backlash at Tobacco Conference
DUBLIN, IRELAND / ACCESS Newswire / June 23, 2025 / On the eve of the World Conference on Tobacco Control (WCTC), a lightshow illuminated the conference centre in Dublin, sending a clear message: millions of consumers are being left out of the conversation on global tobacco and nicotine policy. The event, organised by the World Vapers' Alliance, launched the " Voices Unheard - Consumers Matter! " campaign to highlight the ongoing marginalisation of those most affected by tobacco control decisions. With COP11 in Geneva on the horizon, the campaign underscores the urgent need for consumer representation in policymaking. While hundreds of experts and officials discuss regulations behind closed doors, the light show symbolises the voices of countless adults who have successfully quit smoking with safer alternatives, yet remain unheard in critical policy debates. Michael Landl, Director of the World Vapers' Alliance, criticised the influence of powerful figures such as Michael Bloomberg, whose support for prohibitionist policies often sidelines consumer perspectives. 'Policymakers must listen to those whose lives are directly impacted by these decisions,' Landl said. 'Evidence, not ideology or the influence of wealthy donors, should guide regulations.' The campaign also addresses recent calls from the World Health Organization for bans on flavoured nicotine products, which advocates argue would deny adults access to life-saving alternatives. Alberto Gómez Hernández, Policy and Advocacy Manager for the WVA, emphasised, 'Banning flavours is not about protection-it's about denying adults the tools they need to quit smoking.' The World Vapers' Alliance continues to call for evidence-based harm reduction policies and genuine consumer inclusion as the world prepares for COP11. For media enquiries, please contact: Michael Landl [email protected] +436648412958 High-quality pictures can be found here. More information about flavour bans: More about the WVA's demands: SOURCE: World Vapers' Alliance press release
